Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Trial of Adjuvant Pembrolizumab in Patients With Limited Stage Small Cell Lung Cancer

NCT06140407 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT06140407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06140407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Trial of Adjuvant Pembrolizumab in Patients With Limited Stage Small Cell Lung Cancer
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
February 14, 2024
Completion date
May 27, 2025
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage lung small cell carcinoma, stage i lung cancer, stage ii lung cancer, stage iii lung cancer